Label: UNITHROID- levothyroxine sodium tablet

  • NDC Code(s): 60846-801-01, 60846-802-01, 60846-803-01, 60846-804-01, view more
    60846-805-01, 60846-806-01, 60846-807-01, 60846-808-01, 60846-809-01, 60846-810-01, 60846-811-01, 60846-812-01
  • Packager: Amneal Pharmaceuticals LLC
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: New Drug Application

Drug Label Information

Updated June 28, 2019

If you are a consumer or patient please visit this version.

  • HIGHLIGHTS OF PRESCRIBING INFORMATION
    These highlights do not include all the information needed to use UNITHROID safely and effectively. See full prescribing information for UNITHROID.

    UNITHROID® (levothyroxine sodium) tablets, for oral use
    Initial U.S. Approval: 2001

    WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS

    See full prescribing information for complete boxed warning.

    • Thyroid hormones, including UNITHROID, should not be used for the treatment of obesity or for weight loss.
    • Doses beyond the range of daily hormonal requirements may produce serious or even life threatening manifestations of toxicity (6, 10).

    INDICATIONS AND USAGE

    UNITHROID is L-thyroxine (T4) indicated in pediatric and adult patients for:

    • Hypothyroidism: As replacement in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. (1)
    • Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. (1)

    Limitations of Use:

    • Not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients. (1)
    • Not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis. (1)

    DOSAGE AND ADMINISTRATION

    Administer once daily, on an empty stomach, one-half to one hour before breakfast with a full glass of water. (2.1)

    Administer at least 4 hours before or after drugs that are known to interfere with absorption (2.1)

    Evaluate the need for dose adjustments when regularly administering within one hour of certain foods that may affect absorption. (2.1)

    Starting dose depends on a variety of factors, including age, body weight, cardiovascular status, concomitant medical conditions (including pregnancy), concomitant medications, co-administered food, and the specific nature of the condition being treated. Peak therapeutic effect may not be attained for 4 to 6 weeks. (2.2)

    See full prescribing information for dosing in specific patient populations. (2.3)

    Adequacy of therapy determined with periodic monitoring of TSH and/or T4 as well as clinical status. (2.4)

    DOSAGE FORMS AND STRENGTHS

    Tablets: 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200mcg, 300 mcg (3)

    CONTRAINDICATIONS

    Uncorrected adrenal insufficiency (4)

    WARNINGS AND PRECAUTIONS

    Cardiac adverse reactions in the elderly and in patients with underlying cardiovascular disease: Initiate UNITHROID at less than the full replacement dose because of the increased risk of cardiac adverse reactions, including atrial fibrillation (2.3, 5.1, 8.5)

    Myxedema coma: Do not use oral thyroid hormone drug products to treat myxedema coma. (5.2)

    Acute adrenal crisis in patients with concomitant adrenal insufficiency: Treat with replacement glucocorticoids prior to initiation of UNITHROID treatment (5.3)

    Prevention of hyperthyroidism or incomplete treatment of hypothyroidism: Proper dose titration and careful monitoring is critical to prevent the persistence of hypothyroidism or the development of hyperthyroidism. (5.4)

    Worsening of diabetic control: Therapy in patients with diabetes mellitus may worsen glycemic control and result in increased antidiabetic agent or insulin requirements. Carefully monitor glycemic control after starting, changing, or discontinuing thyroid hormone therapy (5.5)

    Decreased bone mineral density associated with thyroid hormone over-replacement: Over-replacement can increase bone resorption and decrease bone mineral density. Give the lowest effective dose (5.6)

    ADVERSE REACTIONS

    Common adverse reactions for UNITHROID are primarily those of hyperthyroidism due to therapeutic overdosage: arrhythmias, myocardial infarction, dyspnea, muscle spasm, headache, nervousness, irritability, insomnia, tremors, muscle weakness, increased appetite, weight loss, diarrhea, heat intolerance, menstrual irregularities, and skin rash (6)

    To report SUSPECTED ADVERSE REACTIONS, Amneal Pharmaceuticals Inc. at 1-877-835-5472 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

    DRUG INTERACTIONS

    See full prescribing information for drugs that affect thyroid hormone pharmacokinetics and metabolism (e.g., absorption, synthesis, secretion, catabolism, protein binding, and target tissue response) and may alter the therapeutic response to UNITHROID (7)

    USE IN SPECIFIC POPULATIONS

    Pregnancy may require the use of higher doses of levothyroxine (2.3, 8.1

    See 17 for PATIENT COUNSELING INFORMATION.

    Revised: 6/2019

  • Table of Contents

    FULL PRESCRIBING INFORMATION: CONTENTS*

    WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS

    1 INDICATIONS AND USAGE

    2 DOSAGE AND ADMINISTRATION

    2.1 General Administration Information

    2.2 General Principles of Dosing

    2.3 Dosing in Specific Populations

    2.4 Monitoring TSH and/or Thyroxine (T4) Levels

    3 DOSAGE FORMS AND STRENGTHS

    4 CONTRAINDICATIONS

    5 WARNINGS AND PRECAUTIONS

    5.1 Cardiac Adverse Reactions in the Elderly and in Patients with Underlying Cardiovascular Disease

    5.2 Myxedema Coma

    5.3 Acute Adrenal Crisis in Patients with Concomitant Adrenal Insufficiency

    5.4 Prevention of Hyperthyroidism or Incomplete Treatment of Hypothyroidism

    5.5 Worsening of Diabetic Control

    5.6 Decreased Bone Mineral Density Associated with Thyroid Hormone Over-Replacement

    6 ADVERSE REACTIONS

    7 DRUG INTERACTIONS

    7.1 Drugs Known to Affect Thyroid Hormone Pharmacokinetics

    7.2 Antidiabetic Therapy

    7.3 Oral Anticoagulants

    7.4 Digitalis Glycosides

    7.5 Antidepressant Therapy

    7.6 Ketamine

    7.7 Sympathomimetics

    7.8 Tyrosine-Kinase Inhibitors

    7.9 Drug-Food Interactions

    7.10 Drug-Laboratory Test Interactions

    8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    8.2 Lactation

    8.4 Pediatric Use

    8.5 Geriatric Use

    10 OVERDOSAGE

    11 DESCRIPTION

    12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    12.2 Pharmacodynamics

    12.3 Pharmacokinetics

    13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

    16 HOW SUPPLIED/STORAGE AND HANDLING

    17 PATIENT COUNSELING INFORMATION

    *
    Sections or subsections omitted from the full prescribing information are not listed.
  • BOXED WARNING (What is this?)

    WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS

    • Thyroid hormones, including UNITHROID, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss.
    • In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction.
    • Larger doses may produce serious or even life threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects [see Adverse Reactions (6), Drug Interactions (7.7), and Overdosage (10)].
  • 1 INDICATIONS AND USAGE

    Hypothyroidism

    UNITHROID is indicated in pediatric and adult patients as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism.

    Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression

    UNITHROID is indicated in pediatric and adult patients as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.

    Limitations of Use:

    • UNITHROID is not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with UNITHROID may induce hyperthyroidism [see Warnings and Precautions (5.4)].
    • UNITHROID is not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis.
  • 2 DOSAGE AND ADMINISTRATION

    2.1 General Administration Information

    Administer UNITHROID tablets orally as a single daily dose, on an empty stomach, one-half to one hour before breakfast.

    Administer UNITHROID at least 4 hours before or after drugs that are known to interfere with UNITHROID absorption [see Drug Interactions (7.1)].

    Evaluate the need for dose adjustments when regularly administering within one hour of certain foods that may affect UNITHROID absorption [see Drug Interactions (7.9), Clinical Pharmacology (12.3)].

    Administer UNITHROID to infants and children who cannot swallow intact tablets by crushing the tablet, suspending the freshly crushed tablet in a small amount (5 mL to 10 mL or 1 teaspoon to 2 teaspoons) of water and immediately administering the suspension by spoon or dropper. Do not store the suspension. Do not administer in foods that decrease absorption of UNITHROID, such as soybean-based infant formula [see Drug Interactions (7.9)].

    2.2 General Principles of Dosing

    The dose of UNITHROID for hypothyroidism or pituitary TSH suppression depends on a variety of factors including: the patient's age, body weight, cardiovascular status, concomitant medical conditions (including pregnancy), concomitant medications, co-administered food and the specific nature of the condition being treated [see Dosage and Administration (2.3), Warnings and Precautions (5), Drug Interactions (7)]. Dosing must be individualized to account for these factors and dose adjustments made based on periodic assessment of the patient's clinical response and laboratory parameters [see Dosage and Administration (2.4)].

    The peak therapeutic effect of a given dose of UNITHROID may not be attained for 4 to 6 weeks.

    2.3 Dosing in Specific Populations

    Primary Hypothyroidism in Adults and in Adolescents in Whom Growth and Puberty Are Complete

    Start UNITHROID at the full replacement dose in otherwise healthy, non-elderly individuals who have been hypothyroid for only a short time (such as a few months). The average full replacement dose of UNITHROID is approximately 1.6 mcg per kg per day (for example: 100 mcg per day to 125 mcg per day for a 70 kg adult).

    Adjust the dose by 12.5 mcg to 25 mcg increments every 4 to 6 weeks until the patient is clinically euthyroid and the serum TSH returns to normal. Doses greater than 200 mcg per day are seldom required. An inadequate response to daily doses of greater than 300 mcg per day is rare and may indicate poor compliance, malabsorption, drug interactions, or a combination of these factors.

    For elderly patients or patients with underlying cardiac disease, start with a dose of 12.5 mcg to 25 mcg per day. Increase the dose every 6 to 8 weeks, as needed until the patient is clinically euthyroid and the serum TSH returns to normal. The full replacement dose of UNITHROID may be less than 1 mcg per kg per day in elderly patients.

    In patients with severe longstanding hypothyroidism, start with a dose of 12.5 mcg to 25 mcg per day. Adjust the dose in 12.5 mcg to 25 mcg increments every 2 to 4 weeks until the patient is clinically euthyroid and the serum TSH level is normalized.

    Secondary or Tertiary Hypothyroidism

    Start UNITHROID at the full replacement dose in otherwise healthy, non-elderly individuals. Start with a lower dose in elderly patients, patients with underlying cardiovascular disease or patients with severe longstanding hypothyroidism as described above. Serum TSH is not a reliable measure of UNITHROID dose adequacy in patients with secondary or tertiary hypothyroidism and should not be used to monitor therapy. Use the serum free-T4 level to monitor adequacy of therapy in this patient population. Titrate UNITHROID dosing per above instructions until the patient is clinically euthyroid and the serum free-T4 level is restored to the upper half of the normal range.

    Pediatric Dosage - Congenital or Acquired Hypothyroidism 

    The recommended daily dose of UNITHROID in pediatric patients with hypothyroidism is based on body weight and changes with age as described in Table 1. Start UNITHROID at the full daily dose in most pediatric patients. Start at a lower starting dose in newborns (0 to 3 months) at risk for cardiac failure and in children at risk for hyperactivity (see below). Monitor for clinical and laboratory response [see Dosage and Administration (2.4)].

    Table 1: UNITHROID Dosing Guidelines for Pediatric Hypothyroidism
    AgeDaily Dose Per Kg Body Weight a
    0 to 3 months10 mcg/kg daily to 15 mcg/kg daily
    3 to 6 months8 mcg/kg daily to 10 mcg/kg daily
    6 to 12 months6 mcg/kg daily to 8 mcg/kg daily
    1 to 5 years5 mcg/kg to 6 mcg/kg daily
    6 to 12 years4 mcg/kg to 5 mcg/kg daily
    Greater than 12 years but growth and puberty incomplete2 mcg/kg to 3 mcg/kg daily
    Growth and puberty complete 1.6 mcg/kg daily
    a - The dose should be adjusted based on clinical response and laboratory parameters [see Warnings and Precautions (5.4), Drug Interactions (7.10), and Use In Specific Populations (8.4)].

    Newborns (0 to 3 months) at Risk for Cardiac Failure:

    Consider a lower starting dose in newborns at risk for cardiac failure. Increase the dose every 4 to 6 weeks as needed based on clinical and laboratory response.

    Pediatric Patients at Risk for Hyperactivity:

    To minimize the risk of hyperactivity in pediatric patients, start at one-fourth the recommended full replacement dose, and increase on a weekly basis by one-fourth the full recommended replacement dose until the full recommended replacement dose is reached.

    Pregnancy

    Pre-existing Hypothyroidism: UNITHROID dose requirements may increase during pregnancy. Measure serum TSH and free-T4 as soon as pregnancy is confirmed and, at minimum, during each trimester of pregnancy. In patients with primary hypothyroidism, maintain serum TSH in the trimester-specific reference range. For patients with serum TSH above the normal trimester-specific range, increase the dose of UNITHROID by 12.5 mcg daily to 25 mcg daily and measure TSH every 4 weeks until a stable UNITHROID dose is reached and serum TSH is within the normal trimester-specific range. Reduce UNITHROID dosage to pre-pregnancy levels immediately after delivery and measure serum TSH levels 4 to 8 weeks postpartum to ensure UNITHROID dose is appropriate.

    New Onset Hypothyroidism: Normalize thyroid function as rapidly as possible. In patients with moderate to severe signs and symptoms of hypothyroidism, start UNITHROID at the full replacement dose (1.6 mcg per kg body weight per day). In patients with mild hypothyroidism (TSH less than 10 mIU per liter) start UNITHROID at 1 mcg per kg body weight per day. Evaluate serum TSH every 4 weeks and adjust UNITHROID dosage until a serum TSH is within the normal trimester specific range [see Use in Specific Populations (8.1)].

    TSH Suppression in Well-Differentiated Thyroid Cancer

    The dose of UNITHROID should target TSH levels within the desired therapeutic range. This may require a UNITHROID dose of greater than 2 mcg per kg per day, depending on the target level for TSH suppression.

    2.4 Monitoring TSH and/or Thyroxine (T4) Levels

    Assess the adequacy of therapy by periodic assessment of laboratory tests and clinical evaluation. Persistent clinical and laboratory evidence of hypothyroidism despite an apparent adequate replacement dose of UNITHROID may be evidence of inadequate absorption, poor compliance, drug interactions, or a combination of these factors.

    Adults

    In adult patients with primary hypothyroidism, monitor serum TSH levels after an interval of 6 to 8 weeks after any change in dose. In patients on a stable and appropriate replacement dose, evaluate clinical and biochemical response every 6 to 12 months and whenever there is a change in the patient’s clinical status.

    Pediatrics

    In patients with congenital hypothyroidism, assess the adequacy of replacement therapy by measuring both serum TSH and total or free-T. Monitor TSH and total or free-T4 in children as follows: 2 and 4 weeks after the initiation of treatment, 2 weeks after any change in dosage, and then every 3 to 12 months thereafter following dose stabilization until growth is completed. Poor compliance or abnormal values may necessitate more frequent monitoring. Perform routine clinical examination, including assessment of development, mental and physical growth, and bone maturation, at regular intervals.

    While the general aim of therapy is to normalize the serum TSH level, TSH may not normalize in some patients due to in utero hypothyroidism causing a resetting of pituitary-thyroid feedback. Failure of the serum T4 to increase into the upper half of the normal range within 2 weeks of initiation of UNITHROID therapy and/or of the serum TSH to decrease below 20 mIU per liter within 4 weeks may indicate the child is not receiving adequate therapy. Assess compliance, dose of medication administered, and method of administration prior to increasing the dose of UNITHROID [see Warnings and Precautions (5.1) and Use in Specific Populations (8.4)])].

    Secondary and Tertiary Hypothyroidism

    Monitor serum free-T4 levels and maintain in the upper half of the normal range in these patients.

  • 3 DOSAGE FORMS AND STRENGTHS

    UNITHROID tablets are round and color-coded available as follows:

    Strength (mcg) ColorTablet Markings
    25PeachJSP / 513
    50WhiteJSP / 514
    75PurpleJSP / 515
    88OliveJSP / 561
    100YellowJSP / 516
    112RoseJSP / 562
    125TanJSP / 519
    137BlueJSP / 564
    150Light BlueJSP / 520
    175LilacJSP / 563
    200PinkJSP / 522
    300GreenJSP / 523
  • 4 CONTRAINDICATIONS

    UNITHROID is contraindicated in patients with uncorrected adrenal insufficiency [see Warnings and Precautions (5.3)].

  • 5 WARNINGS AND PRECAUTIONS

    5.1 Cardiac Adverse Reactions in the Elderly and in Patients with Underlying Cardiovascular Disease

    Overtreatment with levothyroxine may cause an increase in heart rate, cardiac wall thickness, and cardiac contractility and may precipitate angina or arrhythmias, particularly in patients with cardiovascular disease and in elderly patients. Initiate UNITHROID therapy in this population at lower doses than those recommended in younger individuals or in patients without cardiac disease [see Dosage and Administration (2.3), Use in Specific Populations (8.5)].

    Monitor for cardiac arrhythmias during surgical procedures in patients with coronary artery disease receiving suppressive UNITHROID therapy. Monitor patients receiving concomitant UNITHROID and sympathomimetic agents for signs and symptoms of coronary insufficiency. If cardiovascular symptoms develop or worsen, reduce or withhold the UNITHROID dose for one week and restart at a lower dose. 

    5.2 Myxedema Coma

    Myxedema coma is a life-threatening emergency characterized by poor circulation and hypometabolism, and may result in unpredictable absorption of levothyroxine sodium from the gastrointestinal tract. Use of oral thyroid hormone drug products is not recommended to treat myxedema coma. Administer thyroid hormone products formulated for intravenous administration to treat myxedema coma.

    5.3 Acute Adrenal Crisis in Patients with Concomitant Adrenal Insufficiency

    Thyroid hormone increases metabolic clearance of glucocorticoids. Initiation of thyroid hormone therapy prior to initiating glucocorticoid therapy may precipitate an acute adrenal crisis in patients with adrenal insufficiency. Treat patients with adrenal insufficiency with replacement glucocorticoids prior to initiating treatment with UNITHROID [see Contraindications (4)].

    5.4 Prevention of Hyperthyroidism or Incomplete Treatment of Hypothyroidism

    UNITHROID has a narrow therapeutic index. Over- or under-treatment with UNITHROID may have negative effects on growth and development, cardiovascular function, bone metabolism, reproductive function, cognitive function, emotional state, gastrointestinal function, and on glucose and lipid metabolism. Titrate the dose of UNITHROID carefully and monitor response to titration to avoid these effects [see Dosage and Administration (2.4)]. Monitor for the presence of drug or food interactions when using UNITHROID and adjust the dose as necessary [see Drug Interactions (7), Clinical Pharmacology (12.3)].

    5.5 Worsening of Diabetic Control

    Addition of levothyroxine therapy in patients with diabetes mellitus may worsen glycemic control and result in increased antidiabetic agent or insulin requirements. Carefully monitor glycemic control after starting, changing, or discontinuing UNITHROID [see Drug Interactions (7.2)].

    5.6 Decreased Bone Mineral Density Associated with Thyroid Hormone Over-Replacement

    Increased bone resorption and decreased bone mineral density may occur as a result of levothyroxine over-replacement, particularly in post-menopausal women. The increased bone resorption may be associated with increased serum levels and urinary excretion of calcium and phosphorous, elevations in bone alkaline phosphatase, and suppressed serum parathyroid hormone levels. Administer the minimum dose of UNITHROID that achieves the desired clinical and biochemical response to mitigate against this risk.

  • 6 ADVERSE REACTIONS

    Common adverse reactions with UNITHROID therapy are primarily those of hyperthyroidism due to therapeutic overdosage [see Warnings and Precautions (5.4) and Overdosage (10)]. They include the following:

    General: fatigue, increased appetite, weight loss, heat intolerance, fever, excessive sweating

    Central nervous system: headache, hyperactivity, nervousness, anxiety, irritability, emotional lability, insomnia

    Musculoskeletal: tremors, muscle weakness and cramps

    Cardiovascular: palpitations, tachycardia, arrhythmias, increased pulse and blood pressure, heart failure, angina, myocardial infarction, cardiac arrest

    Respiratory: dyspnea

    Gastrointestinal: diarrhea, vomiting, abdominal cramps, elevations in liver function tests

    Dermatologic: hair loss, flushing

    Endocrine: decreased bone mineral density

    Reproductive: menstrual irregularities, impaired fertility


    Seizures have been reported rarely with levothyroxine therapy.


    Adverse Reactions in Pediatric Patients

    Pseudotumor cerebri and slipped capital femoral epiphysis have been reported in pediatric patients receiving levothyroxine therapy. Overtreatment may result in craniosynostosis in infants and premature closure of the epiphyses in pediatric patients with resultant compromised adult height.

    Hypersensitivity Reactions

    Hypersensitivity reactions to inactive ingredients have occurred in patients treated with thyroid hormone products. These include urticaria, pruritus, skin rash, flushing, angioedema, various gastrointestinal symptoms (abdominal pain, nausea, vomiting and diarrhea), fever, arthralgia, serum sickness and wheezing. Hypersensitivity to levothyroxine itself is not known to occur.

  • 7 DRUG INTERACTIONS

    7.1 Drugs Known to Affect Thyroid Hormone Pharmacokinetics

    Many drugs can exert effects on thyroid hormone pharmacokinetics (e.g. absorption, synthesis, secretion, catabolism, protein binding, and target tissue response) and may alter the therapeutic response to UNITHROID (see Tables 2 – 5).

    Table 2: Drugs That May Decrease T4 Absorption (Hypothyroidism)
    Potential impact: Concurrent use may reduce the efficacy of UNITHROID by binding and delaying or preventing absorption, potentially resulting in hypothyroidism.
    Drug or Drug ClassEffect
    Calcium Carbonate
    Ferrous Sulfate
    Calcium carbonate may form an insoluble chelate with levothyroxine, and ferrous sulfate likely forms a ferric-thyroxine complex. Administer UNITHROID at least 4 hours apart from these agents.
    OrlistatMonitor patients treated concomitantly with orlistat and UNITHROID for changes in thyroid function.
    Bile Acid Sequestrants
    -Colesevelam
    -Cholestyramine
    -Colestipol
    Ion Exchange Resins
    -Kayexalate
    -Sevelamer
    Bile acid sequestrants and ion exchange resins are known to decrease levothyroxine absorption. Administer UNITHROID at least 4 hours prior to these drugs or monitor thyrotropin-stimulating hormone (TSH) levels.
    Other drugs:
    Proton Pump Inhibitors
    Sucralfate
    Antacids
    - Aluminum & Magnesium Hydroxides
    - Simethicone
    Gastric acidity is an essential requirement for adequate absorption of levothyroxine. Sucralfate, antacids and proton pump inhibitors may cause hypochlorhydria, affect intragastric pH, and reduce levothyroxine absorption. Monitor patients appropriately.
    Table 3: Drugs That May Alter T and Triiodothyronine (T3) Serum Transport Without Affecting Free Thyroxine (FT4) Concentration (Euthyroidism)
    Drug or Drug ClassEffect
    Clofibrate
    Estrogen-containing oral contraceptives
    Estrogens (oral)
    Heroin / Methadone
    5-Fluorouracil
    Mitotane
    Tamoxifen
    These drugs may increase serum thyroxine-binding globulin (TBG) concentration.
    Androgens / Anabolic Steroids
    Asparaginase
    Glucocorticoids
    Slow-Release Nicotinic Acid
    These drugs may decrease serum TBG concentration.
    Potential impact (below): Administration of these agents with UNITHROID results in an initial transient increase in FT4. Continued administration results in a decrease in serum T4 and normal FT4 and TSH concentrations.
    Salicylates (>2 g/day)Salicylates inhibit binding of T4 and T3 to TBG and transthyretin. An initial increase in serum FT4 is followed by return of FT4 to normal levels with sustained therapeutic serum salicylate concentrations, although total T4 levels may decrease by as much as 30%.
    Other drugs:
    Carbamazepine
    Furosemide (>80 mg IV)
    Heparin
    Hydantoins
    Non-Steroidal Anti-inflammatory Drugs
    - Fenamates
    These drugs may cause protein-binding site displacement. Furosemide has been shown to inhibit the protein binding of T4 to TBG and albumin, causing an increased free-T4 fraction in serum. Furosemide competes for T4-binding sites on TBG, prealbumin, and albumin, so that a single high dose can acutely lower the total T4 level. Phenytoin and carbamazepine reduce serum protein binding of levothyroxine, and total and FT4 may be reduced by 20% to 40%, but most patients have normal serum TSH levels and are clinically euthyroid. Closely monitor thyroid hormone parameters.
    Table 4: Drugs That May Alter Hepatic Metabolism of T4 (Hypothyroidism)
    Potential impact: Stimulation of hepatic microsomal drug-metabolizing enzyme activity may cause increased hepatic degradation of levothyroxine, resulting in increased UNITHROID requirements.
    Drug or Drug ClassEffect
    Phenobarbital
    Rifampin
    Phenobarbital has been shown to reduce the response to thyroxine. Phenobarbital increases L-thyroxine metabolism by inducing uridine 5'-diphospho-glucuronosyltransferase (UGT) and leads to a lower T4 serum levels. Changes in thyroid status may occur if barbiturates are added or withdrawn from patients being treated for hypothyroidism. Rifampin has been shown to accelerate the metabolism of levothyroxine.
    Table 5: Drugs That May Decrease Conversion of T4 to T3
    Potential impact: Administration of these enzyme inhibitors decreases the peripheral conversion of T4 to T3, leading to decreased T3 levels. However, serum T4 levels are usually normal but may occasionally be slightly increased.
    Drug or Drug ClassEffect
    Beta-adrenergic antagonists
    (e.g., Propranolol >160 mg/day)
    In patients treated with large doses of propranolol (>160 mg/day), T3 and T4 levels change slightly, TSH levels remain normal, and patients are clinically euthyroid. It should be noted that actions of particular beta-adrenergic antagonists may be impaired when the hypothyroid patient is converted to the euthyroid state.
    Glucocorticoids (e.g., Dexamethasone ≥4 mg/day)Short-term administration of large doses of glucocorticoids may decrease serum T3 concentrations by 30% with minimal change in serum T4 levels. However, long-term glucocorticoid therapy may result in slightly decreased T3 and T4 levels due to decreased TBG production (See above).
    Other:
    Amiodarone
    Amiodarone inhibits peripheral conversion of levothyroxine (T4) to triiodothyronine (T3) and may cause isolated biochemical changes (increase in serum free-T4, and decreased or normal free-T3) in clinically euthyroid patients.

    7.2 Antidiabetic Therapy

    Addition of UNITHROID therapy in patients with diabetes mellitus may worsen glycemic control and result in increased antidiabetic agent or insulin requirements. Carefully monitor glycemic control, especially when UNITHROID is started, changed, or discontinued [see Warnings and Precautions (5.5)].

    7.3 Oral Anticoagulants

    UNITHROID increases the response to oral anticoagulant therapy. Therefore, a decrease in the dose of anticoagulant may be warranted with correction of the hypothyroid state or when the UNITHROID dose is increased. Closely monitor coagulation tests to permit appropriate and timely dosage adjustments.

    7.4 Digitalis Glycosides

    UNITHROID may reduce the therapeutic effects of digitalis glycosides. Serum digitalis glycoside levels may be decreased when a hypothyroid patient becomes euthyroid, necessitating an increase in the dose of digitalis glycosides.

    7.5 Antidepressant Therapy

    Concurrent use of tricyclic (e.g., amitriptyline) or tetracyclic (e.g., maprotiline) antidepressants and UNITHROID may increase the therapeutic and toxic effects of both drugs, possibly due to increased receptor sensitivity to catecholamines. Toxic effects may include increased risk of cardiac arrhythmias and central nervous system stimulation. UNITHROID may accelerate the onset of action of tricyclics. Administration of sertraline in patients stabilized on UNITHROID may result in increased UNITHROID requirements.

    7.6 Ketamine

    Concurrent use of ketamine and UNITHROID may produce marked hypertension and tachycardia. Closely monitor blood pressure and heart rate in these patients.

    7.7 Sympathomimetics

    Concurrent use of sympathomimetics and UNITHROID may increase the effects of sympathomimetics or thyroid hormone. Thyroid hormones may increase the risk of coronary insufficiency when sympathomimetic agents are administered to patients with coronary artery disease.

    7.8 Tyrosine-Kinase Inhibitors

    Concurrent use of tyrosine-kinase inhibitors such as imatinib may cause hypothyroidism. Closely monitor TSH levels in such patients.

    7.9 Drug-Food Interactions

    Consumption of certain foods may affect UNITHROID absorption thereby necessitating adjustments in dosing [see Dosage and Administration (2.1)]. Soybean flour (infant formula), cotton seed meal, walnuts, and dietary fiber may bind and decrease the absorption of UNITHROID from the GI tract. Grapefruit juice may delay the absorption of levothyroxine and reduce its bioavailability.

    7.10 Drug-Laboratory Test Interactions

    Consider changes in TBG concentration when interpreting T4 and T3 values. Measure and evaluate unbound (free) hormone and/or determine the free T4 index (FT4I) in this circumstance. Pregnancy, infectious hepatitis, estrogens, estrogen-containing oral contraceptives, and acute intermittent porphyria increase TBG concentrations. Nephrosis, severe hypoproteinemia, severe liver disease, acromegaly, androgens and corticosteroids decrease TBG concentration. Familial hyper- or hypo-thyroxine binding globulinemias have been described, with the incidence of TBG deficiency approximating 1 in 9000.

  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Risk Summary

    Experience with levothyroxine use in pregnant women, including data from post-marketing studies, have not reported increased rates of major birth defects or miscarriages (see Data). There are risks to the mother and fetus associated with untreated hypothyroidism in pregnancy. Since thyroid-stimulating hormone (TSH) levels may increase during pregnancy, TSH should be monitored and UNITHROID dosage adjusted during pregnancy (see Clinical Considerations). There are no animal studies conducted with levothyroxine during pregnancy. UNITHROID should not be discontinued during pregnancy and hypothyroidism diagnosed during pregnancy should be promptly treated.

    The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

    Clinical Considerations

    Disease-Associated Maternal and/or Embryo/Fetal Risk

    Maternal hypothyroidism during pregnancy is associated with a higher rate of complications, including spontaneous abortion, gestational hypertension, pre-eclampsia, stillbirth, and premature delivery. Untreated maternal hypothyroidism may have an adverse effect on fetal neurocognitive development.

    Dose Adjustments During Pregnancy and the Postpartum Period

    Pregnancy may increase UNITHROID requirements. Serum TSH level should be monitored and the UNITHROID dosage adjusted during pregnancy. Since postpartum TSH levels are similar to preconception values, the UNITHROID dosage should return to the pre-pregnancy dose immediately after delivery   [see  Dosage and Administration  (2.3)]

    Data

    Human Data

    Levothyroxine is approved for use as a replacement therapy for hypothyroidism. There is a long experience of levothyroxine use in pregnant women, including data from post-marketing studies that have not reported increased rates of fetal malformations, miscarriages or other adverse maternal or fetal outcomes associated with levothyroxine use in pregnant women.

    8.2 Lactation

    Risk Summary

    Limited published studies report that levothyroxine is present in human milk. However, there is insufficient information to determine the effects of levothyroxine on the breastfed infant and no available information on the effects of levothyroxine on milk production. Adequate levothyroxine treatment during lactation may normalize milk production in hypothyroid lactating mothers. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for UNITHROID and any potential adverse effects on the breastfed infant from UNITHROID or from the underlying maternal condition.

    8.4 Pediatric Use

    The initial dose of UNITHROID varies with age and body weight. Dosing adjustments are based on an assessment of the individual patient’s clinical and laboratory parameters [see Dosage and Administration (2.3, 2.4)].

    In children in whom a diagnosis of permanent hypothyroidism has not been established, discontinue UNITHROID for a trial period, but only after the child is at least 3 years of age. Obtain serum T4 and TSH levels at the end of the trial period, and use laboratory test results and clinical assessments to guide diagnosis and treatment, if warranted.

    Congenital Hypothyroidism [see Dosage and Administration (2.3, 2.4)]

    Rapid restoration of normal serum T4 concentrations is essential for preventing the adverse effects of congenital hypothyroidism on intellectual development as well as on overall physical growth and maturation. Therefore, initiate UNITHROID therapy immediately upon diagnosis. Levothyroxine is generally continued for life in these patients. 

    Closely monitor infants during the first 2 weeks of UNITHROID therapy for cardiac overload, arrhythmias, and aspiration from avid suckling.

    Closely monitor patients to avoid undertreatment or overtreatment. Undertreatment may have deleterious effects on intellectual development and linear growth. Overtreatment is associated with craniosynostosis in infants, may adversely affect the tempo of brain maturation, and may accelerate the bone age and result in premature epiphyseal closure and compromised adult stature.

    Acquired Hypothyroidism in Pediatric Patients

    Closely monitor patients to avoid undertreatment and overtreatment. Undertreatment may result in poor school performance due to impaired concentration and slowed mentation and in reduced adult height. Overtreatment may accelerate the bone age and result in premature epiphyseal closure and compromised adult stature. 

    Treated children may manifest a period of catch-up growth, which may be adequate in some cases to normalize adult height. In children with severe or prolonged hypothyroidism, catch-up growth may not be adequate to normalize adult height.

    8.5 Geriatric Use

    Because of the increased prevalence of cardiovascular disease among the elderly, initiate UNITHROID at less than the full replacement dose [see Dosage and Administration (2.3) and Warnings and Precautions (5.1)]. Atrial arrhythmias can occur in elderly patients. Atrial fibrillation is the most common of the arrhythmias observed with levothyroxine overtreatment in the elderly. 

  • 10 OVERDOSAGE

    The signs and symptoms of overdosage are those of hyperthyroidism [see Warnings and Precautions (5.4) and Adverse Reactions (6)]. In addition, confusion and disorientation may occur. Cerebral embolism, shock, coma, and death have been reported. Seizures occurred in a 3-year-old child ingesting 3.6 mg of levothyroxine. Symptoms may not necessarily be evident or may not appear until several days after ingestion of levothyroxine sodium. Reduce the UNITHROID dose or temporarily discontinued if signs or symptoms of overdosage occur. Initiate appropriate supportive treatment as dictated by the patient’s medical status. For current information on the management of poisoning or overdosage, contact the National Poison Control Center at 1‑800-222-1222 or www.poison.org.

  • 11 DESCRIPTION

    UNITHROID contains the active ingredient, levothyroxine, a synthetic crystalline levothyroxine (T4) in sodium salt form. It is chemically designated as L-3,3’,5,5’-tetraiodothyronine monosodium hydrate. Synthetic T4 is identical in chemical structure to the T4 produced in the human thyroid gland. Levothyroxine sodium has an empirical formula of C15H10I4N NaO4 • H2O, molecular weight of 798.85 g/mol (anhydrous), and structural formula as shown:

    UNITHROID_structural_formula

    UNITHROID tablets for oral administration are supplied in the following strengths: 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg and 300 mcg.

    Inactive Ingredients

    Acacia, colloidal silicon dioxide, corn starch, lactose, magnesium stearate, microcrystalline cellulose, and sodium starch glycolate. The following are the coloring additives per tablet strength:

    Strength (mcg)Color additive(s)
    25FD&C Yellow No. 6 Aluminum Lake
    50None
    75FD&C Red No. 40 Aluminum Lake, FD&C Blue No. 2 Aluminum Lake
    88D&C Yellow No. 10 Aluminum Lake, FD&C Yellow No. 6 Aluminum Lake, FD&C Blue No. 1 Aluminum Lake
    100D&C Yellow No. 10 Aluminum Lake, FD&C Yellow No. 6 Aluminum Lake
    112D&C Red No. 27 Aluminum Lake
    125FD&C Yellow No. 6 Aluminum Lake, FD&C Red No. 40 Aluminum Lake, FD&C Blue No. 1 Aluminum Lake
    137FD&C Blue No. 1 Aluminum Lake
    150FD&C Blue No. 2 Aluminum Lake
    175FD&C Blue No. 1 Aluminum Lake, D&C Red No. 27 Aluminum Lake
    200FD&C Red No. 40 Aluminum Lake
    300D&C Yellow No. 10 Aluminum Lake, FD&C Yellow No. 6 Aluminum Lake, FD&C Blue No. 1 Aluminum Lake
  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    Thyroid hormones exert their physiologic actions through control of DNA transcription and protein synthesis. Triiodothyronine (T3) and L-thyroxine (T4) diffuse into the cell nucleus and bind to thyroid receptor proteins attached to DNA. This hormone nuclear receptor complex activates gene transcription and synthesis of messenger RNA and cytoplasmic proteins.

    The physiological actions of thyroid hormones are produced predominantly by T3, the majority of which (approximately 80%) is derived from T4 by deiodination in peripheral tissues.

    12.2 Pharmacodynamics

    Oral levothyroxine sodium is a synthetic T4 hormone that exerts the same physiologic effect as endogenous T4, thereby maintaining normal T4 levels when a deficiency is present.

    12.3 Pharmacokinetics

    Absorption

    Absorption of orally administered T4 from the gastrointestinal tract ranges from 40% to 80%. The majority of the levothyroxine dose is absorbed from the jejunum and upper ileum. The relative bioavailability of UNITHROID tablets, compared to an equal nominal dose of oral levothyroxine sodium solution, is approximately 97 to 99%. T4 absorption is increased by fasting, and decreased in malabsorption syndromes and by certain foods such as soybeans. Dietary fiber decreases bioavailability of T4. Absorption may also decrease with age. In addition, many drugs and foods affect T4 absorption [see Drug Interactions (7)].

    Distribution

    Circulating thyroid hormones are greater than 99% bound to plasma proteins, including thyroxine-binding globulin (TBG), thyroxine‑binding prealbumin (TBPA), and thyroxine-binding albumin (TBA), whose capacities and affinities vary for each hormone. The higher affinity of both TBG and TBPA for T4 partially explains the higher serum levels, slower metabolic clearance, and longer half‑life of T4 compared to T3. Protein-bound thyroid hormones exist in reverse equilibrium with small amounts of free hormone. Only unbound hormone is metabolically active. Many drugs and physiologic conditions affect the binding of thyroid hormones to serum proteins [see Drug Interactions (7)]. Thyroid hormones do not readily cross the placental barrier [see Use in Specific Populations (8.1)].

    Elimination

    Metabolism 

    T4 is slowly eliminated (Table 6). The major pathway of thyroid hormone metabolism is through sequential deiodination. Approximately 80 % of circulating T3 is derived from peripheral T4 by monodeiodination. The liver is the major site of degradation for both T4 and T3, with T4 deiodination also occurring at a number of additional sites, including the kidney and other tissues. Approximately 80% of the daily dose of T4 is deiodinated to yield equal amonts of T3 and reverse T3 (r T3). T3 and rT3 are further deiodinated to diiodothyronine. Thyroid hormones are also metabolized via conjugation with glucuronides and sulfates and excreted directly into the bile and gut where they undergo enterohepatic recirculation.

    Excretion

    Thyroid hormones are primarily eliminated by the kidneys. A portion of the conjugated hormone reaches the colon unchanged and is eliminated in the feces. Approximately 20% of T4 is eliminated in the stool. Urinary excretion of T4 decreases with age.

    Table 6: Pharmacokinetic Parameters of Thyroid Hormones in Euthyroid Patients
    Hormone Ratio in
    Thyroglobulin
    Biologic Potency
    (days)
    Protein Binding
    (%)2
    Levothyroxine (T4)10–2016–7199.96
    Liothyronine (T3)14≤ 299.5

    1 3 to 4 days in hyperthyroidism, 9 to 10 days in hypothyroidism 
    2 Includes TBG, TBPA, and TBA

  • 13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

    Animal studies have not been performed to evaluate the carcinogenic potential, mutagenic potential or effects on fertility of levothyroxine sodium.

  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    UNITHROID (levothyroxine sodium) tablets are round and color-coded available as follows:

    Strength
    (mcg)
    Color Tablet
    Markings
    NDC - bottles of 100
    25PeachJSP / 513NDC 60846-801-01
    50WhiteJSP / 514NDC 60846-802-01
    75PurpleJSP / 515NDC 60846-803-01
    88OliveJSP / 561NDC 60846-804-01
    100YellowJSP / 516NDC 60846-805-01
    112RoseJSP / 562NDC 60846-806-01
    125TanJSP / 519NDC 60846-807-01
    137BlueJSP / 564NDC 60846-808-01
    150Light BlueJSP / 520NDC 60846-809-01
    175LilacJSP / 563NDC 60846-810-01
    200PinkJSP / 522NDC 60846-811-01
    300GreenJSP / 523NDC 60846-812-01

    STORAGE CONDITIONS

    Store between 20°C-25°C (68°F-77°F) with excursions permitted between 15°C-30°C (59°F-86°F).

  • 17 PATIENT COUNSELING INFORMATION

    Dosing and Administration

    • Instruct patients to take UNITHROID only as directed by their healthcare provider.

    • Instruct patients to take UNITHROID as a single dose, preferably on an empty stomach, one-half to one hour before breakfast with a full glass of water to avoid choking or gagging.

    • Inform patients that agents such as iron and calcium supplements and antacids can decrease the absorption of levothyroxine. Instruct patients not to take UNITHROID tablets within 4 hours of these agents.

    • Instruct patients to notify their healthcare provider should they become pregnant or breastfeeding or are thinking of becoming pregnant, while taking UNITHROID.

    Important Information

    • Inform patients that it may take several weeks before they notice an improvement in symptoms.
    • Inform patients that the levothyroxine in UNITHROID is intended to replace a hormone that is normally produced by the thyroid gland. Generally, replacement therapy is to be taken for life.
    • Inform patients that UNITHROID should not be used as a primary or adjunctive therapy in a weight control program.
    • Instruct patients to notify their healthcare provider if they are taking any other medications, including prescription and over‑the-counter preparations.
    • Instruct patients to notify their healthcare provider of any other medical conditions you may have, particularly heart disease, diabetes, clotting disorders, and adrenal or pituitary gland problems as the dose of medications used to control these other conditions may need to be adjusted while taking UNITHROID. If they have diabetes, instruct patients to monitor their blood and/or urinary glucose levels as directed by their physician and immediately report any changes to their physician. If patients are taking anticoagulants, their clotting status should be checked frequently.
    • Instruct patients to notify their physician or dentist if they are taking UNITHROID prior to any surgery.

    Adverse Reactions

    • Instruct patients to notify their healthcare provider if they experience any of the following symptoms: rapid or irregular heartbeat, chest pain, shortness of breath, leg cramps, headache, nervousness, irritability, sleeplessness, tremors, change in appetite, weight gain or loss, vomiting, diarrhea, excessive sweating, heat intolerance, fever, changes in menstrual periods, hives or skin rash, or any other unusual medical event
    • Inform patients that partial hair loss may occur rarely during the first few months of UNITHROID therapy; this is usually temporary.

    Manufactured by:
    Jerome Stevens Pharmaceuticals, Inc.

    Bohemia, NY 11716

    Distributed by:
    Amneal Specialty, a division of Amneal Pharmaceuticals LLC
    Bridgewater, NJ 08807

    Revised: 06/2019

  • PRINCIPAL DISPLAY PANEL - 25 mcg (0.025 mg)

    jsp

    NDC 60846-801-01

    UNITHROID®

    (Levothyroxine
    Sodium Tablets, USP)

    25 mcg
    (0.025 mg)

    Rx ONLY

    100 TABLETS

    25
  • PRINCIPAL DISPLAY PANEL - 50 mcg (0.05 mg)

    jsp

    NDC 60846-802-01

    UNITHROID®

    (Levothyroxine
    Sodium Tablets, USP)

    50 mcg
    (0.05 mg)

    Rx ONLY

    100 TABLETS

     

    50

  • PRINCIPAL DISPLAY PANEL - 75 mcg (0.075 mg)

    jsp

    NDC 60846-803-01

    UNITHROID®

    (Levothyroxine
    Sodium Tablets, USP)

    75 mcg
    (0.075 mg)

    Rx ONLY

    100 TABLETS

    75
  • PRINCIPAL DISPLAY PANEL - 88 mcg (0.088 mg)

    jsp

    NDC 60846-804-01

    UNITHROID®

    (Levothyroxine
    Sodium Tablets, USP)

    88 mcg
    (0.088 mg)

    Rx ONLY

    100 TABLETS

    88
  • PRINCIPAL DISPLAY PANEL - 100 mcg (0.1 mg)

    jsp

    NDC 60846-805-01

    UNITHROID®

    (Levothyroxine
    Sodium Tablets, USP)

    100 mcg
    (0.1 mg)

    Rx ONLY

    100 TABLETS

    100
  • PRINCIPAL DISPLAY PANEL - 112 mcg (0.112 mg)

    jsp

    NDC 60846-806-01

    UNITHROID®

    (Levothyroxine
    Sodium Tablets, USP)

    112 mcg
    (0.112 mg)

    Rx ONLY

    100 TABLETS

    112
  • PRINCIPAL DISPLAY PANEL - 125 mcg (0.125 mg)

    jsp

    NDC 60846-807-01

    UNITHROID®

    (Levothyroxine
    Sodium Tablets, USP)

    125 mcg
    (0.125 mg)

    Rx ONLY

    100 TABLETS

    125
  • PRINCIPAL DISPLAY PANEL - 137 mcg (0.137 mg)

    jsp

    NDC 60846-808-01

    UNITHROID®

    (Levothyroxine
    Sodium Tablets, USP)

    137 mcg
    (0.137 mg)

    Rx ONLY

    100 TABLETS

    137
  • PRINCIPAL DISPLAY PANEL - 150 mcg (0.15 mg)

    jsp

    NDC 60846-809-01

    UNITHROID®

    (Levothyroxine
    Sodium Tablets, USP)

    150 mcg
    (0.15 mg)

    Rx ONLY

    100 TABLETS

    150

  • PRINCIPAL DISPLAY PANEL - 175 mcg (0.175 mg)

    jsp

    NDC 60846-810-01

    UNITHROID®

    (Levothyroxine
    Sodium Tablets, USP)

    175 mcg
    (0.175 mg)

    Rx ONLY

    100 TABLETS

    175
  • PRINCIPAL DISPLAY PANEL - 200 mcg (0.2 mg)

    jsp

    NDC 60846-811-01

    UNITHROID®

    (Levothyroxine
    Sodium Tablets, USP)

    200 mcg
    (0.200 mg)

    Rx ONLY

    100 TABLETS

    200
  • PRINCIPAL DISPLAY PANEL - 300 mcg (0.3 mg)

    jsp

    NDC 60846-812-01

    UNITHROID®

    (Levothyroxine
    Sodium Tablets, USP)

    300 mcg
    (0.300 mg)

    Rx ONLY

    100 TABLETS

    300
  • INGREDIENTS AND APPEARANCE
    UNITHROID 
    levothyroxine sodium tablet
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:60846-801
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    levothyroxine sodium (UNII: 9J765S329G) (levothyroxine - UNII:Q51BO43MG4) levothyroxine sodium anhydrous25 ug
    Inactive Ingredients
    Ingredient NameStrength
    silicon dioxide (UNII: ETJ7Z6XBU4)  
    Lactose, Unspecified Form (UNII: J2B2A4N98G)  
    magnesium stearate (UNII: 70097M6I30)  
    cellulose, microcrystalline (UNII: OP1R32D61U)  
    starch, corn (UNII: O8232NY3SJ)  
    acacia (UNII: 5C5403N26O)  
    sodium starch glycolate type a potato (UNII: 5856J3G2A2)  
    FD&C Yellow No. 6 (UNII: H77VEI93A8)  
    Product Characteristics
    ColorORANGE (Peach) Score2 pieces
    ShapeROUND (ROUND) Size7mm
    FlavorImprint Code JSP;513
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:60846-801-01100 in 1 BOTTLE; Type 0: Not a Combination Product07/03/2014
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDANDA02121007/03/2014
    UNITHROID 
    levothyroxine sodium tablet
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:60846-810
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    levothyroxine sodium (UNII: 9J765S329G) (levothyroxine - UNII:Q51BO43MG4) levothyroxine sodium anhydrous175 ug
    Inactive Ingredients
    Ingredient NameStrength
    silicon dioxide (UNII: ETJ7Z6XBU4)  
    Lactose, Unspecified Form (UNII: J2B2A4N98G)  
    magnesium stearate (UNII: 70097M6I30)  
    cellulose, microcrystalline (UNII: OP1R32D61U)  
    starch, corn (UNII: O8232NY3SJ)  
    acacia (UNII: 5C5403N26O)  
    sodium starch glycolate type a potato (UNII: 5856J3G2A2)  
    FD&C Blue No. 1 (UNII: H3R47K3TBD)  
    D&C Red No. 27 (UNII: 2LRS185U6K)  
    Product Characteristics
    ColorPURPLE (Lilac) Score2 pieces
    ShapeROUND (ROUND) Size7mm
    FlavorImprint Code JSP;563
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:60846-810-01100 in 1 BOTTLE; Type 0: Not a Combination Product07/03/2014
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDANDA02121007/03/2014
    UNITHROID 
    levothyroxine sodium tablet
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:60846-811
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    levothyroxine sodium (UNII: 9J765S329G) (levothyroxine - UNII:Q51BO43MG4) levothyroxine sodium anhydrous200 ug
    Inactive Ingredients
    Ingredient NameStrength
    silicon dioxide (UNII: ETJ7Z6XBU4)  
    Lactose, Unspecified Form (UNII: J2B2A4N98G)  
    magnesium stearate (UNII: 70097M6I30)  
    cellulose, microcrystalline (UNII: OP1R32D61U)  
    starch, corn (UNII: O8232NY3SJ)  
    acacia (UNII: 5C5403N26O)  
    sodium starch glycolate type a potato (UNII: 5856J3G2A2)  
    FD&C Red No. 40 (UNII: WZB9127XOA)  
    Product Characteristics
    ColorPINK (PINK) Score2 pieces
    ShapeROUND (ROUND) Size7mm
    FlavorImprint Code JSP;522
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:60846-811-01100 in 1 BOTTLE; Type 0: Not a Combination Product07/03/2014
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDANDA02121007/03/2014
    UNITHROID 
    levothyroxine sodium tablet
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:60846-812
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    levothyroxine sodium (UNII: 9J765S329G) (levothyroxine - UNII:Q51BO43MG4) levothyroxine sodium anhydrous300 ug
    Inactive Ingredients
    Ingredient NameStrength
    silicon dioxide (UNII: ETJ7Z6XBU4)  
    Lactose, Unspecified Form (UNII: J2B2A4N98G)  
    magnesium stearate (UNII: 70097M6I30)  
    cellulose, microcrystalline (UNII: OP1R32D61U)  
    starch, corn (UNII: O8232NY3SJ)  
    acacia (UNII: 5C5403N26O)  
    sodium starch glycolate type a potato (UNII: 5856J3G2A2)  
    D&C Yellow No. 10 (UNII: 35SW5USQ3G)  
    FD&C Yellow No. 6 (UNII: H77VEI93A8)  
    fd&c blue no. 1 (UNII: H3R47K3TBD)  
    Product Characteristics
    ColorGREEN (GREEN) Score2 pieces
    ShapeROUND (ROUND) Size7mm
    FlavorImprint Code JSP;523
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:60846-812-01100 in 1 BOTTLE; Type 0: Not a Combination Product07/03/2014
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDANDA02121007/03/2014
    UNITHROID 
    levothyroxine sodium tablet
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:60846-802
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    levothyroxine sodium (UNII: 9J765S329G) (levothyroxine - UNII:Q51BO43MG4) levothyroxine sodium anhydrous50 ug
    Inactive Ingredients
    Ingredient NameStrength
    silicon dioxide (UNII: ETJ7Z6XBU4)  
    Lactose, Unspecified Form (UNII: J2B2A4N98G)  
    magnesium stearate (UNII: 70097M6I30)  
    cellulose, microcrystalline (UNII: OP1R32D61U)  
    starch, corn (UNII: O8232NY3SJ)  
    acacia (UNII: 5C5403N26O)  
    sodium starch glycolate type a potato (UNII: 5856J3G2A2)  
    Product Characteristics
    ColorWHITE (WHITE) Score2 pieces
    ShapeROUND (ROUND) Size7mm
    FlavorImprint Code JSP;514
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:60846-802-01100 in 1 BOTTLE; Type 0: Not a Combination Product07/03/2014
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDANDA02121007/03/2014
    UNITHROID 
    levothyroxine sodium tablet
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:60846-803
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    levothyroxine sodium (UNII: 9J765S329G) (levothyroxine - UNII:Q51BO43MG4) levothyroxine sodium anhydrous75 ug
    Inactive Ingredients
    Ingredient NameStrength
    silicon dioxide (UNII: ETJ7Z6XBU4)  
    Lactose, Unspecified Form (UNII: J2B2A4N98G)  
    magnesium stearate (UNII: 70097M6I30)  
    cellulose, microcrystalline (UNII: OP1R32D61U)  
    starch, corn (UNII: O8232NY3SJ)  
    acacia (UNII: 5C5403N26O)  
    sodium starch glycolate type a potato (UNII: 5856J3G2A2)  
    FD&C Red No. 40 (UNII: WZB9127XOA)  
    FD&C Blue No. 2 (UNII: L06K8R7DQK)  
    Product Characteristics
    ColorPURPLE (PURPLE) Score2 pieces
    ShapeROUND (ROUND) Size7mm
    FlavorImprint Code JSP;515
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:60846-803-01100 in 1 BOTTLE; Type 0: Not a Combination Product07/03/2014
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDANDA02121007/03/2014
    UNITHROID 
    levothyroxine sodium tablet
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:60846-804
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    levothyroxine sodium (UNII: 9J765S329G) (levothyroxine - UNII:Q51BO43MG4) levothyroxine sodium anhydrous88 ug
    Inactive Ingredients
    Ingredient NameStrength
    silicon dioxide (UNII: ETJ7Z6XBU4)  
    Lactose, Unspecified Form (UNII: J2B2A4N98G)  
    magnesium stearate (UNII: 70097M6I30)  
    cellulose, microcrystalline (UNII: OP1R32D61U)  
    starch, corn (UNII: O8232NY3SJ)  
    acacia (UNII: 5C5403N26O)  
    sodium starch glycolate type a potato (UNII: 5856J3G2A2)  
    D&C Yellow No. 10 (UNII: 35SW5USQ3G)  
    FD&C Yellow No. 6 (UNII: H77VEI93A8)  
    FD&C Blue No. 1 (UNII: H3R47K3TBD)  
    Product Characteristics
    ColorGREEN (Olive) Score2 pieces
    ShapeROUND (ROUND) Size7mm
    FlavorImprint Code JSP;561
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:60846-804-01100 in 1 BOTTLE; Type 0: Not a Combination Product07/03/2014
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDANDA02121007/03/2014
    UNITHROID 
    levothyroxine sodium tablet
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:60846-805
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    levothyroxine sodium (UNII: 9J765S329G) (levothyroxine - UNII:Q51BO43MG4) levothyroxine sodium anhydrous100 ug
    Inactive Ingredients
    Ingredient NameStrength
    silicon dioxide (UNII: ETJ7Z6XBU4)  
    Lactose, Unspecified Form (UNII: J2B2A4N98G)  
    magnesium stearate (UNII: 70097M6I30)  
    cellulose, microcrystalline (UNII: OP1R32D61U)  
    starch, corn (UNII: O8232NY3SJ)  
    acacia (UNII: 5C5403N26O)  
    sodium starch glycolate type a potato (UNII: 5856J3G2A2)  
    D&C Yellow No. 10 (UNII: 35SW5USQ3G)  
    FD&C Yellow No. 6 (UNII: H77VEI93A8)  
    Product Characteristics
    ColorYELLOW (YELLOW) Score2 pieces
    ShapeROUND (ROUND) Size7mm
    FlavorImprint Code JSP;516
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:60846-805-01100 in 1 BOTTLE; Type 0: Not a Combination Product07/03/2014
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDANDA02121007/03/2014
    UNITHROID 
    levothyroxine sodium tablet
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:60846-806
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    levothyroxine sodium (UNII: 9J765S329G) (levothyroxine - UNII:Q51BO43MG4) levothyroxine sodium anhydrous112 ug
    Inactive Ingredients
    Ingredient NameStrength
    silicon dioxide (UNII: ETJ7Z6XBU4)  
    Lactose, Unspecified Form (UNII: J2B2A4N98G)  
    magnesium stearate (UNII: 70097M6I30)  
    cellulose, microcrystalline (UNII: OP1R32D61U)  
    starch, corn (UNII: O8232NY3SJ)  
    acacia (UNII: 5C5403N26O)  
    sodium starch glycolate type a potato (UNII: 5856J3G2A2)  
    D&C Red No. 27 (UNII: 2LRS185U6K)  
    Product Characteristics
    ColorRED (Rose) Score2 pieces
    ShapeROUND (ROUND) Size7mm
    FlavorImprint Code JSP;562
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:60846-806-01100 in 1 BOTTLE; Type 0: Not a Combination Product07/03/2014
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDANDA02121007/03/2014
    UNITHROID 
    levothyroxine sodium tablet
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:60846-807
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    levothyroxine sodium (UNII: 9J765S329G) (levothyroxine - UNII:Q51BO43MG4) levothyroxine sodium anhydrous125 ug
    Inactive Ingredients
    Ingredient NameStrength
    silicon dioxide (UNII: ETJ7Z6XBU4)  
    Lactose, Unspecified Form (UNII: J2B2A4N98G)  
    magnesium stearate (UNII: 70097M6I30)  
    cellulose, microcrystalline (UNII: OP1R32D61U)  
    starch, corn (UNII: O8232NY3SJ)  
    acacia (UNII: 5C5403N26O)  
    sodium starch glycolate type a potato (UNII: 5856J3G2A2)  
    FD&C Yellow No. 6 (UNII: H77VEI93A8)  
    FD&C Red No. 40 (UNII: WZB9127XOA)  
    FD&C Blue No. 1 (UNII: H3R47K3TBD)  
    Product Characteristics
    ColorBROWN (Tan) Score2 pieces
    ShapeROUND (ROUND) Size7mm
    FlavorImprint Code JSP;519
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:60846-807-01100 in 1 BOTTLE; Type 0: Not a Combination Product07/03/2014
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDANDA02121007/03/2014
    UNITHROID 
    levothyroxine sodium tablet
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:60846-808
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    levothyroxine sodium (UNII: 9J765S329G) (levothyroxine - UNII:Q51BO43MG4) levothyroxine sodium anhydrous137 ug
    Inactive Ingredients
    Ingredient NameStrength
    silicon dioxide (UNII: ETJ7Z6XBU4)  
    Lactose, Unspecified Form (UNII: J2B2A4N98G)  
    magnesium stearate (UNII: 70097M6I30)  
    cellulose, microcrystalline (UNII: OP1R32D61U)  
    starch, corn (UNII: O8232NY3SJ)  
    acacia (UNII: 5C5403N26O)  
    sodium starch glycolate type a potato (UNII: 5856J3G2A2)  
    FD&C Blue No. 1 (UNII: H3R47K3TBD)  
    Product Characteristics
    ColorBLUE (BLUE) Score2 pieces
    ShapeROUND (ROUND) Size7mm
    FlavorImprint Code JSP;564
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:60846-808-01100 in 1 BOTTLE; Type 0: Not a Combination Product07/03/2014
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDANDA02121007/03/2014
    UNITHROID 
    levothyroxine sodium tablet
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:60846-809
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    levothyroxine sodium (UNII: 9J765S329G) (levothyroxine - UNII:Q51BO43MG4) levothyroxine sodium anhydrous150 ug
    Inactive Ingredients
    Ingredient NameStrength
    silicon dioxide (UNII: ETJ7Z6XBU4)  
    Lactose, Unspecified Form (UNII: J2B2A4N98G)  
    magnesium stearate (UNII: 70097M6I30)  
    cellulose, microcrystalline (UNII: OP1R32D61U)  
    starch, corn (UNII: O8232NY3SJ)  
    acacia (UNII: 5C5403N26O)  
    sodium starch glycolate type a potato (UNII: 5856J3G2A2)  
    FD&C Blue No. 2 (UNII: L06K8R7DQK)  
    Product Characteristics
    ColorBLUE (Light Blue) Score2 pieces
    ShapeROUND (ROUND) Size7mm
    FlavorImprint Code JSP;520
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:60846-809-01100 in 1 BOTTLE; Type 0: Not a Combination Product07/03/2014
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDANDA02121007/03/2014
    Labeler - Amneal Pharmaceuticals LLC (123797875)